DARIN BRANSON: Open Payments
NPI 1255711909 · GRAY, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,406 in 41 payments from 14 companies in 2025. Trend: 2023 $858 · 2024 $1,698 · 2025 $1,406
Food & beverage: $1,346Education: $60
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 7 | $291 |
| Novo Nordisk Inc | 9 | $240 |
| Vanda Pharmaceuticals Inc. | 8 | $204 |
| Amgen Inc. | 1 | $147 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $136 |
| GlaxoSmithKline, LLC. | 1 | $104 |
| ABBVIE INC. | 3 | $92 |
| Astellas Pharma US Inc | 1 | $60 |
| Lilly USA, LLC | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
Products named: Auvelity, FANAPT, Ozempic, KRYSTEXXA, CAPLYTA, VRAYLAR, REXULTI, MOUNJARO.
Industry payments across LA — which companies pay providers there.
